GH Research Q3 net loss narrows as costs fall
Overview
Biopharma firm's Q3 net loss narrowed yr/yr as R&D and G&A expenses declined
Company ended Q3 with $350.6 mln in cash, cash equivalents and marketable securities
Company received positive initial FDA feedback on pivotal TRD program, expects End-of-Phase 2 meeting in Q1 2027
Outlook
GH Research expects End-of-Phase 2 FDA meeting for TRD program in Q1 2027
Company plans to initiate TRD pivotal program shortly after FDA meeting, pending alignment
GH Research targets PPD pivotal program initiation in H2 2027, subject to regulatory alignment
Result Drivers
LOWER R&D EXPENSES - Co said Q3 research and development expenses fell due to decreased technical and clinical development costs
LOWER G&A EXPENSES - Co said Q3 general and administrative expenses declined due to lower professional fees
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Loss Per Share | $0.18 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for GH Research PLC is $39.50, about 113.6% above its November 12 closing price of $18.49
Reuters Recommended Reads
Nov 12 - Fractyl Health's Q3 net loss narrows as costs fall, shifts focus to Revita
Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall
Nov 12 - Prime Medicine Q3 loss narrows as expenses decline
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)